Atossa Therapeutics, Inc. (BMV:ATOS)

Market Cap	1.84B
Revenue (ttm)	n/a
Net Income (ttm)	-541.57M
Shares Out	n/a
EPS (ttm)	-4.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,734
Average Volume	1,844
Open	14.50
Previous Close	14.36
Day's Range	14.30 - 14.50
52-Week Range	13.00 - 31.00
Beta	n/a
RSI	38.69
Earnings Date	Aug 13, 2025

About Atossa Therapeutics

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Thera...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 15
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ATOS

Financial Performance

Financial numbers in USD